Harrow Health Intrinsic Stock Value – Investors of Harrow Health, Urged to Contact Pomerantz Law Firm for Investigation in 2023.

March 18, 2023

Trending News 🌥️

Harrow Health ($NASDAQ:HROW), Inc. (HARR) investors have been urged to contact Pomerantz Law Firm regarding an investigation into the company’s activities in 2023. The firm has expressed concerns that the company may have engaged in securities fraud or other wrongful conduct. As such, shareholders are encouraged to contact the firm if they have suffered losses as a result of investing in HARR. They are experienced in providing strategic legal advice to those who have experienced financial losses due to corporate wrongdoing. If you believe you have been harmed by Harrow Health, Inc. (HARR), please contact the firm for further information and examine your legal options.

It is important for investors to take action when they believe they have been wronged. The Pomerantz Law Firm is dedicated to protecting shareholders’ rights and offers free consultations to those who think they may have been impacted by securities fraud or other wrongful conduct. Don’t wait; contact the firm now for an evaluation of your legal options.

Stock Price

This follows that there has been mainly positive media coverage surrounding the company so far. On Monday, HARROW HEALTH stock opened at $17.6 and closed at $18.2, an increase of 3.5% from the prior closing price of 17.6. This suggests that investors are bullish on the company and its prospects. However, it is important for shareholders to keep informed and invest wisely, thus the call for an investigation by Pomerantz Law Firm. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Harrow Health. More…

    Total Revenues Net Income Net Margin
    88.45 -22.56 -21.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Harrow Health. More…

    Operations Investing Financing
    3.93 -15.94 -0.89
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Harrow Health. More…

    Total Assets Total Liabilities Book Value Per Share
    98.99 98.13 0.04
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Harrow Health are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    21.0% -0.8%
    FCF Margin ROE ROA
    -27.8% -13.3% -0.5%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Harrow Health Intrinsic Stock Value

    At GoodWhale, we recently took a look at the fundamentals of HARROW HEALTH. Our proprietary Valuation Line showed an intrinsic value of $9.8 per share for the stock. That means that it is currently overvalued by 85.6%, with the stock trading at $18.2. This could mean that the stock is a good buy or a good sell, depending on the investor’s individual goals. We suggest performing further research and considering the potential risks involved before investing in the stock. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • Peers

    Its competitors include Universe Pharmaceuticals Inc, CEN Biotech Inc, and Earth Science Tech Inc.

    – Universe Pharmaceuticals Inc ($NASDAQ:UPC)

    Universe Pharmaceuticals Inc is a pharmaceutical company with a market cap of 25.66M as of 2022. The company has a Return on Equity of 7.88%. Universe Pharmaceuticals Inc is engaged in the research, development, manufacture and sale of pharmaceutical and health products. The company’s products include prescription drugs, over-the-counter drugs, herbal remedies and dietary supplements. Universe Pharmaceuticals Inc is headquartered in New York, New York.

    – CEN Biotech Inc ($OTCPK:CENBF)

    CEN Biotech is a biotech company that focuses on developing and commercializing innovative therapies for the treatment of cancer and other serious diseases. The company has a market cap of 2.73M and a ROE of 97.87%. CEN Biotech is a publicly traded company on the OTCQB market under the ticker symbol “CENB”.

    – Earth Science Tech Inc ($OTCPK:ETST)

    With a market cap of 2.59M, Science Tech Inc is a small company with a ROE of -103.79%. The company focuses on providing innovative engineering and technical solutions to the commercial, industrial, and governmental sectors. Science Tech Inc has a long history of providing quality services and products that meet or exceed customer expectations. The company is committed to providing value to its customers through its products and services.


    Investors of Harrow Health, Inc. have been urged to contact Pomerantz Law Firm for an investigation in 2023. So far media coverage of the company has been positive, and Harrow Health’s stock price rose on the same day the announcement was made. Analysts believe that investing in Harrow Health could be a good opportunity, given the company’s potential growth and the optimistic outlook of their future. With the upcoming investigation, it is important that investors stay up to date on the latest news and developments regarding Harrow Health, so they can make informed decisions on their investments.

    Recent Posts

    Leave a Comment